SURENAC

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating inflammation; Excipients for use in the manufacture of pharmaceuticals; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, medical devices, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Preservatives for pharmaceutical preparations; the foregoing goods containing N-acetylcysteine

Anti-diabetic pharmaceuticals; Capsules sold empty for pharmaceuticals; Cardiovascular pharmaceuticals; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a coating for sustained release formulations that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation, cardiovascular disease (CVD), multiple sclerosis (MS), and pulmonary diseases, including chronic obstructive pulmonary disease (COPD); Pharmaceutical preparations for the treatment and prevention of diabetes, renal disease, colitis; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, antidepressants; the foregoing goods containing N-acetylcysteine